KR20100082349A - 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 - Google Patents

치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 Download PDF

Info

Publication number
KR20100082349A
KR20100082349A KR1020107010481A KR20107010481A KR20100082349A KR 20100082349 A KR20100082349 A KR 20100082349A KR 1020107010481 A KR1020107010481 A KR 1020107010481A KR 20107010481 A KR20107010481 A KR 20107010481A KR 20100082349 A KR20100082349 A KR 20100082349A
Authority
KR
South Korea
Prior art keywords
methyl
phenyl
bipyrrolidinyl
carboxylic acid
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107010481A
Other languages
English (en)
Korean (ko)
Inventor
베른가르트 체크티즈키
중리 가오
윌리엄 제이. 허스트
로타르 슈빙크
지크프리트 스텐겔린
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20100082349A publication Critical patent/KR20100082349A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
KR1020107010481A 2007-10-17 2008-10-14 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도 Ceased KR20100082349A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98060607P 2007-10-17 2007-10-17
US60/980,606 2007-10-17

Publications (1)

Publication Number Publication Date
KR20100082349A true KR20100082349A (ko) 2010-07-16

Family

ID=40248052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107010481A Ceased KR20100082349A (ko) 2007-10-17 2008-10-14 치환된 ｎ－페닐-비피롤리딘 우레아 및 이의 치료적 용도

Country Status (24)

Country Link
US (1) US8222290B2 (https=)
EP (1) EP2215058B1 (https=)
JP (1) JP5380455B2 (https=)
KR (1) KR20100082349A (https=)
CN (1) CN101903341B (https=)
AT (1) ATE534625T1 (https=)
AU (1) AU2008312641A1 (https=)
CA (1) CA2702933C (https=)
CY (1) CY1112391T1 (https=)
DK (1) DK2215058T3 (https=)
ES (1) ES2378011T3 (https=)
HR (1) HRP20120166T1 (https=)
IL (1) IL205002A0 (https=)
MA (1) MA31889B1 (https=)
MX (1) MX2010003948A (https=)
MY (1) MY148807A (https=)
NZ (1) NZ584692A (https=)
PL (1) PL2215058T3 (https=)
PT (1) PT2215058E (https=)
RS (1) RS52221B (https=)
RU (1) RU2478094C2 (https=)
SI (1) SI2215058T1 (https=)
WO (1) WO2009052068A1 (https=)
ZA (1) ZA201002114B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903340B (zh) * 2007-10-17 2013-03-27 赛诺菲-安万特 取代的n-苯基联吡咯烷羧酰胺及其治疗用途
CN101903342B (zh) * 2007-10-17 2012-11-21 赛诺菲-安万特 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途
EP2212282B1 (en) 2007-10-17 2011-09-21 Sanofi Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
KR100940437B1 (ko) 2008-06-13 2010-02-10 주식회사 엘지화학 발열체 및 이의 제조방법
KR20090129927A (ko) 2008-06-13 2009-12-17 주식회사 엘지화학 발열체 및 이의 제조방법
US10412788B2 (en) 2008-06-13 2019-09-10 Lg Chem, Ltd. Heating element and manufacturing method thereof
EP2569297A1 (en) 2010-05-11 2013-03-20 Sanofi Substituted n-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof
WO2011143155A1 (en) 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
AR083718A1 (es) 2010-05-11 2013-03-20 Sanofi Aventis Fenil cicloalquil pirrolidina (piperidina) espirolactamas y amidas sustituidas, preparacion y uso terapeutico de las mismas
JP5833105B2 (ja) 2010-05-11 2015-12-16 サノフイ 置換ｎ−ヘテロアリールスピロラクタムビピロリジン類、その製造及び治療的使用
TW201206889A (en) 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
TW201206898A (en) * 2010-05-11 2012-02-16 Sanofi Aventis Substituted N-phenyl spirolactam bipyrrolidines, preparation and therapeutic use thereof
WO2011143162A1 (en) * 2010-05-11 2011-11-17 Sanofi Substituted n-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
EP2694492B1 (en) * 2011-02-23 2015-07-29 Suven Life Sciences Limited Novel compounds as histamine h3 receptor ligands

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
US7279491B2 (en) * 2002-10-23 2007-10-09 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2006227815B2 (en) 2005-03-17 2011-09-22 Eli Lilly And Company Pyrrolidine derivatives as histamine H3 receptor antagonists
AU2006232871B9 (en) * 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1904442B1 (en) * 2005-07-01 2011-09-07 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
CA2627234A1 (en) * 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
CN101903340B (zh) 2007-10-17 2013-03-27 赛诺菲-安万特 取代的n-苯基联吡咯烷羧酰胺及其治疗用途
EP2212282B1 (en) 2007-10-17 2011-09-21 Sanofi Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
CN101903342B (zh) 2007-10-17 2012-11-21 赛诺菲-安万特 取代的n-苯基-吡咯烷基甲基吡咯烷酰胺及其作为组胺h3受体调节剂的治疗用途

Also Published As

Publication number Publication date
EP2215058A1 (en) 2010-08-11
NZ584692A (en) 2011-12-22
CA2702933C (en) 2012-12-18
PL2215058T3 (pl) 2012-04-30
ES2378011T3 (es) 2012-04-04
RU2010119554A (ru) 2011-11-27
HK1146056A1 (en) 2011-05-13
CN101903341B (zh) 2012-10-03
HRP20120166T1 (hr) 2012-03-31
RU2478094C2 (ru) 2013-03-27
DK2215058T3 (da) 2012-03-12
JP2011500697A (ja) 2011-01-06
PT2215058E (pt) 2012-03-06
ATE534625T1 (de) 2011-12-15
US20100173908A1 (en) 2010-07-08
EP2215058B1 (en) 2011-11-23
CY1112391T1 (el) 2015-12-09
ZA201002114B (en) 2010-12-29
CN101903341A (zh) 2010-12-01
RS52221B (sr) 2012-10-31
WO2009052068A1 (en) 2009-04-23
JP5380455B2 (ja) 2014-01-08
MX2010003948A (es) 2010-04-30
AU2008312641A1 (en) 2009-04-23
SI2215058T1 (sl) 2012-03-30
MA31889B1 (fr) 2010-12-01
IL205002A0 (en) 2010-11-30
US8222290B2 (en) 2012-07-17
MY148807A (en) 2013-05-31
CA2702933A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
US8222290B2 (en) Substituted N-phenyl-bipyrrolidine ureas and therapeutic use thereof
JP5377503B2 (ja) 置換されたｎ−フェニル−ビピロリジンカルボキサミド及びその治療上の使用
US8618159B2 (en) Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
US8227504B2 (en) Substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof
US8383814B2 (en) Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof
US8871788B2 (en) Substituted N-alkyl and N-acyl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
US8859588B2 (en) Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof
HK1146056B (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
HK1146053B (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131011

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150223

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150521

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I